What Brilinta 90mg treats: main uses and benefits

Brilinta 90mg is utilized in combination with aspirin to help manage the risk of serious cardiovascular issues in individuals who have experienced acute coronary syndrome (ACS). It helps manage the potential associated with conditions such as unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). These are situations characterized by diminished blood flow to the heart muscle, and this management approach is a key part of therapeutic care. The medication is an approved measure to support blood management following these critical events.

This medication provides a supportive role following a severe cardiac event or after a coronary stent placement. This strategy is intended to offer support in the long-term management of heart health. The goal of therapy is to support management of healthy blood circulation and to help manage the potential for recurrence in specific patient populations.

Quick Facts

Quick Fact: Focus on Cardiovascular Risk The medication is a supportive measure for blood circulation in patients who have experienced an acute coronary event.

Who Can and Cannot Use Brilinta 90mg

Official regulatory guidelines define specific patient populations for whom the use of Brilinta (ticagrelor) is either contraindicated, restricted, or requires special caution. The medication is primarily intended for use in adult patients.

Populations Excluded from Use (Contraindicated)

Category	Regulatory Status
Bleeding Risk	Contraindicated in patients with a History of Intracranial Hemorrhage or Active Pathological Bleeding (e.g., peptic ulcer).
Organ Impairment	Contraindicated in patients with Severe Hepatic Impairment.
Hypersensitivity	Contraindicated in patients allergic to ticagrelor or any component of the product.

Restricted and Limited Use

Category	Regulatory Status
Surgery	Do not start treatment in patients undergoing Urgent Coronary Artery Bypass Graft (CABG) surgery.
Organ Status	Use is not recommended for patients on Renal Dialysis and requires caution in patients with Moderate Hepatic Impairment.
Age	Safety and effectiveness have not been established in pediatric patients (under 18 years of age).
Maternal Status	Use is not recommended during pregnancy or while breastfeeding.

Use requires caution in patient groups with a general propensity to bleed or those with an increased risk of bradycardic events. Dosage adjustments are not required for older adults or those with general renal impairment.

Interactions with other medicines and products

The regulatory interaction profile for Brilinta (ticagrelor) is primarily defined by pharmacokinetic and pharmacodynamic interactions documented in official government prescribing information.

Contraindicated and Avoided Combinations

Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) is contraindicated because these agents significantly increase ticagrelor exposure. Conversely, co-administration with strong CYP3A4 inducers (e.g., rifampin, phenytoin) should be avoided as they substantially decrease ticagrelor exposure, potentially diminishing its intended effect. The use of ticagrelor is also contraindicated in patients with severe hepatic impairment due to the expected increase in drug exposure.

Pharmacokinetic and Pharmacodynamic Effects

Ticagrelor is documented as a mild CYP3A4 inhibitor and a P-glycoprotein (P-gp) inhibitor, which may increase the serum concentrations of co-administered medicines that are substrates for these pathways, such as digoxin and certain statins (e.g., simvastatin or lovastatin). Doses of these statins should not exceed 40 mg when co-administered. The medicine also has a pharmacodynamic additive effect with other agents that increase the risk of bleeding, including oral anticoagulants, fibrinolytics, and NSAIDs.

Restrictions and Timing

Maintenance doses of Aspirin greater than 100 mg daily reduce ticagrelor's effectiveness and should be avoided. For patients undergoing elective surgical procedures, such as CABG, the drug should be discontinued at least 5 days prior to surgery.

P2Y12 Receptor-Mediated Signaling Modulation

This domain covers the direct, non-competitive binding of ticagrelor to the P2Y12 receptor, a critical element in the adenosine diphosphate (ADP)-driven signaling cascade on platelets. This targeted engagement leads to the suppression of receptor activity, reducing the rate of platelet activation and subsequent aggregation responses.

---

Inhibition of Platelet Aggregation Cascade

The binding to the P2Y12 receptor initiates a cascade effect that blocks ADP-mediated signal transduction within the platelet. This modification prevents the required conformational change and activation of the glycoprotein IIb/ IIIa receptor complex, ultimately resulting in diminished signal transduction and reduced downstream activation within the targeted biological pathways.

---

Modification of Primary Hemostasis Pathways

By maintaining the P2Y12 receptor in an inactive state, ticagrelor modifies the signal transduction pathways that drive primary hemostasis. This mechanistic effect results in the suppression of platelet aggregation, thereby modulating a key step in the hemostatic response.

Administration Method

Brilinta tablets are intended for oral use and can be taken with or without food. The tablets should be swallowed whole with a glass of water. For patients who have difficulty swallowing the tablet whole, it can be crushed into a fine powder, mixed in half a glass of water, and consumed immediately. The glass should be rinsed with an additional half glass of water and the contents drunk to ensure the full dose is taken.

Consistency and Routine

To maintain a steady level of the medication in the bloodstream, it is generally recommended to take the doses at the same times each day, such as one tablet in the morning and one in the evening. Establishing a routine helps in managing the treatment schedule effectively.

Missing a Dose

If a scheduled dose is missed, the patient should skip the missed dose and take the next tablet at the regularly scheduled time. Taking two doses at once to make up for a missed dose is not advised.

Duration of Use

This medication is typically used as part of a long-term treatment plan. The duration of therapy is determined based on individual clinical circumstances and the specific underlying cardiovascular condition being managed. It is important to continue the regimen as directed by a healthcare provider, even if the patient feels well, as the medication works to prevent future cardiovascular events.

Research Evidence / Overview of Studies for Brilinta 90mg

This section summarizes the high-level findings and structure of the official research, including key randomized, controlled studies and regulatory reviews that establish the evidence base for Ticagrelor.

---

Research Evidence for Acute Coronary Syndrome (ACS) Management

Research exploring the use of Ticagrelor for Acute Coronary Syndrome (ACS) management involved large, international, randomized, controlled studies. These studies examined the medicine's use in adult patients hospitalized due to a recent ACS event, such as a heart attack or unstable angina. In these research settings, Ticagrelor was studied alongside aspirin and was primarily evaluated against an active comparator in the main trial, rather than a placebo.

The researchers tracked the time until the first occurrence of a composite measure, which included Cardiovascular Death, a new Myocardial Infarction, or Stroke. Studies reported patterns where the measured incidence of this combined outcome differed between the group receiving Ticagrelor and the group receiving the active comparator. A key research point is that patterns of incidence varied across specific geographic regions within the main trial, requiring further analysis.

---

Research Evidence for Long-Term Prevention After Myocardial Infarction (MI)

Research has also explored the use of Ticagrelor in a long-term setting for patients who have a history of a heart attack one to three years prior. These studies used large, international, randomized, double-blind, placebo-controlled trials. The research tracked the same core composite outcome (Cardiovascular Death, MI, or Stroke) over an extended period, typically around three years.

Findings describe patterns observed in these studies, where the measured incidence of the composite outcome differed between the Ticagrelor groups and the group receiving placebo. The study also reported on individual components, including Ischemic Stroke. A research limitation here is that the main long-term trial studied both the 90 mg dose and a lower 60 mg dose. The primary focus of regulatory review for maintenance therapy in this specific long-term secondary prevention context was directed toward a lower dose.

Common questions about Brilinta 90mg (FAQ)

Q: How quickly does Brilinta start working in the body?

A: According to official product information, the medicine starts working quickly after a dose. The maximum effect on reducing platelet activity is generally observed within two to four hours after it is taken.

Q: Can Brilinta cause ringing in the ears?

A: Auditory-related side effects, such as a feeling of pounding in the ears or ringing (tinnitus), have been noted in post-marketing reports. These types of reactions are recorded in official adverse reaction documents.

Q: Does Brilinta make me bleed easily?

A: Official boxed warnings state that this medicine, like other agents in its class, has the potential to cause significant bleeding, which in rare cases has been fatal. Regulatory information indicates that increased bruising and bleeding are known possibilities during its use.

Q: Is it normal to feel short of breath when taking Brilinta?

A: Shortness of breath, medically known as dyspnea, is reported as a common side effect in clinical trials. Official warnings note that this effect is generally described as being self-limiting.

Q: How long do most people stay on Brilinta?

A: Treatment with the 90 mg dose is typically continued for up to 12 months, according to official dosing structures. After this period, official guidance notes that a lower strength may be used for extended, long-term maintenance.

Q: Is Brilinta a blood thinner?

A: Brilinta is officially classified as an antiplatelet agent, not a traditional blood thinner. It works by reducing the ability of platelets—which are a type of blood cell—to clump together, modulating a key part of the blood clotting process.

Q: Is it safe to get dental work or surgery while on Brilinta?

A: Official guidelines note that the medicine should be temporarily stopped for a specified period, such as at least five days, before certain planned surgical procedures. The drug is discontinued because of its effects on blood clotting.

Q: Is Brilinta used for treating strokes, or only heart attacks?

A: The official indications include reducing the risk of cardiovascular death, myocardial infarction (heart attack), and stroke. This scope includes patients who have had an acute ischemic stroke or a transient ischemic attack (TIA).

Q: Are there different brand names for ticagrelor?

A: Yes, ticagrelor is the active ingredient in Brilinta. The product is also known by other brand names in various regions, such as Brilique in many parts of Europe.

Q: What are the most common reasons someone would stop taking Brilinta?

A: Official data indicates that in clinical trials, the most frequent reasons patients discontinued the medicine were related to the occurrence of adverse effects. These commonly included bleeding events and shortness of breath (dyspnea).

Q: Does Brilinta have a Black Box Warning?

A: Yes, Brilinta carries an official Boxed Warning in the product information. This warning concerns the potential risk of serious or fatal bleeding and the reduced effectiveness when the daily aspirin maintenance dose exceeds 100 mg.

Q: Can Brilinta affect my liver function?

A: The use of this medicine is contraindicated (not allowed) in individuals who have severe hepatic (liver) impairment. This precaution is taken because the medicine is cleared through the liver.

Q: Is Brilinta safe for people with kidney problems?

A: Official regulatory guidance states that no dosage adjustment is considered necessary for individuals who have renal (kidney) impairment.

Q: What research led to the approval of Brilinta 90mg?

A: The medicine's official indications and approval are primarily supported by findings from significant clinical trials, such as the PLATO study, which are cited in the regulatory labeling.

Q: Is Brilinta different from aspirin?

A: Yes, Brilinta is a P2Y12 platelet inhibitor, while aspirin works through a different mechanism involving cyclooxygenase inhibition. Both are considered agents that affect platelet aggregation.

Q: Do older adults use a different dose of Brilinta?

A: According to official regulatory guidance regarding specific populations, no dose adjustment is considered necessary for elderly individuals based on age alone.

Q: Can Brilinta make me feel more tired than usual?

A: Unusual tiredness or weakness, which is often referred to as fatigue, has been listed in the official product information as a reported adverse reaction.

Q: Is grapefruit juice a problem when taking Brilinta?

A: Grapefruit and grapefruit juice may cause an increase in the level of the medicine in the body due to their action as CYP3A4 inhibitors. For this reason, official information suggests that avoidance is appropriate.

Q: Does the risk of bleeding go up over time while taking Brilinta?

A: Regulatory warnings indicate that the risk of bleeding is an important consideration that remains present throughout the course of treatment, according to clinical trial data.

Q: Are there specific symptoms that require calling a doctor immediately while on Brilinta?

A: Official patient counseling describes specific signs of serious bleeding that require immediate contact with a healthcare provider. These include pink, red, or brown urine, vomit that looks like coffee grounds, or red or black stools.

Q: Can Brilinta cause or worsen heartburn or stomach issues?

A: The medicine is contraindicated in people with active pathological bleeding, such as a stomach ulcer. Additionally, gastrointestinal complaints like dyspepsia (heartburn) and nausea are listed as common side effects.

Q: Is Brilinta safe for people who have had a past stomach ulcer?

A: The medicine is formally contraindicated in patients with active pathological bleeding, which includes a peptic ulcer. This is due to the inherent increased risk of bleeding when using this type of medicine.

Q: Does Brilinta have to be refrigerated or stored in a specific way?

A: Official storage and handling guidelines specify that the medicine should be stored at controlled room temperature. This typically means temperatures between 68 F to 77 F (20 C to 25 C).

Q: Are there restrictions on who can take Brilinta due to breathing issues?

A: Shortness of breath, or dyspnea, is a commonly reported side effect. The official label discusses this as a warning or precaution in relation to the medicine's use.

Q: Can women who are pregnant or breastfeeding use Brilinta?

A: Official regulatory guidance states that use is generally not recommended during pregnancy because safety has not been fully established. Breastfeeding is also not recommended while taking the medicine.

Q: Why is there a caution about certain heart rhythm drugs and Brilinta?

A: The medicine can inhibit a transport protein called P-glycoprotein, which may increase the concentration of co-administered drugs that rely on this pathway for clearance. This includes certain medicines, such as digoxin, which is used for heart rhythm.

Q: How does my body remove Brilinta?

A: Official pharmacokinetic data indicates that the medicine is primarily cleared from the body through metabolism. This process takes place in the liver and involves the CYP3A4 enzyme pathway.

Q: Is it possible to be allergic to Brilinta?

A: Yes, the medicine is formally contraindicated (must not be used) in patients with a history of hypersensitivity. This refers to an allergic reaction, such as swelling of the face, lips, mouth, or tongue (angioedema), to ticagrelor or any other component of the product.

Q: What kind of follow-up tests are needed while on Brilinta?

A: The official product information mentions the monitoring of certain blood markers. This includes serum creatinine and uric acid levels, which are discussed in the warnings section.

Q: Why is ticagrelor sometimes preferred over clopidogrel?

A: Official regulatory documents note that in a specific population of patients with Acute Coronary Syndrome, the medicine demonstrated a difference compared to clopidogrel in reducing cardiovascular death, myocardial infarction, and stroke over at least the first 12 months, based on clinical trial evidence.

Q: How does Brilinta affect platelet function testing?

A: The medicine can interfere with certain lab tests, which may result in false negative results. This interference is noted for some platelet functional tests, particularly those used to test for Heparin Induced Thrombocytopenia (HIT).

Q: Is taking Brilinta linked to a change in uric acid levels?

A: Yes, official adverse reaction data reports that an increase in serum uric acid concentrations has been observed as a potential adverse effect.

Q: What are the main findings from the PLATO trial for Brilinta?

A: The PLATO trial is the key study cited in the official labeling that supports the medicine’s indications. The study's main finding was that in the studied population of patients with Acute Coronary Syndrome, it showed a reduction in the rate of cardiovascular death, myocardial infarction, and stroke compared to the comparator drug.

Q: Can Brilinta cause a metallic taste in the mouth?

A: A metallic taste, known medically as dysgeusia, is listed in the official adverse reaction data as a commonly reported side effect.

Q: What happens if I stop taking Brilinta suddenly?

A: Official boxed warnings clearly state that stopping the medicine increases the risk of subsequent serious cardiovascular events. This includes the risk of myocardial infarction (heart attack) and stroke.

Q: Does Brilinta interact with popular depression or anxiety medications (SSRIs/SNRIs)?

A: The official label notes that using antiplatelet agents concurrently with other medicines that increase bleeding risk requires caution due to an additive effect. The caution is related to the concomitant use of the medicine with agents such as SSRIs and SNRIs.

Q: What is the goal of dual antiplatelet therapy (DAPT)?

A: The clinical goal of dual antiplatelet therapy (DAPT) is defined by the medicine’s indication: to reduce the rate of serious cardiovascular events, including cardiovascular death, myocardial infarction, and stroke, in patients with high-risk heart conditions.

Q: What food or supplements should I avoid with Brilinta?

A: The medicine interacts with strong CYP3A4 inhibitors, which include certain foods and supplements, such as grapefruit juice. These are generally advised to be avoided because they can increase the level of the drug in the body.

Q: What is the main ingredient in Brilinta 90mg?

A: The main active ingredient in the medicine, as listed in the official product description, is ticagrelor.

Q: What does the term 'antiplatelet' mean?

A: An antiplatelet medicine is one that helps reduce the ability of platelets—which are small blood cells—to clump together. This action modulates the clotting pathway in the blood.

Q: Can I take ibuprofen or naproxen for pain while on Brilinta?

A: Official documents note that the medicine has an additive effect with nonsteroidal anti-inflammatory drugs (NSAIDs), which include ibuprofen and naproxen. This additive effect increases the overall risk of bleeding.

Official Storage and Disposal Requirements

Brilinta 90 mg (ticagrelor) must be stored at Controlled Room Temperature, specifically between 68 F to 77 F (20 C to 25 C), as defined in the official labeling. The tablets must be kept in the original container and maintained tightly closed to protect them from excess heat and moisture and to keep them from freezing.

Child-Safety Storage: The medicine is explicitly required to be stored out of the sight and reach of children.

Disposal: Do not keep expired or unused medication. Disposal must be conducted according to local guidelines, and official instructions recommend asking a healthcare professional or pharmacist for proper disposal advice. Regulatory information mandates that the product must not be thrown into household wastewater or drains to avoid release into the environment.